Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
24 12 2020
Historique:
pubmed: 9 12 2020
medline: 3 2 2021
entrez: 8 12 2020
Statut: ppublish

Résumé

Acid ceramidase (AC) is a cysteine hydrolase that plays a crucial role in the metabolism of lysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive molecules that mediate many biological processes ranging from cell structural integrity, signaling, and cell proliferation to cell death. In the effort to expand the structural diversity of the existing collection of AC inhibitors, a novel class of substituted oxazol-2-one-3-carboxamides were designed and synthesized. Herein, we present the chemical optimization of our initial hits, 2-oxo-4-phenyl-

Identifiants

pubmed: 33290061
doi: 10.1021/acs.jmedchem.0c01561
pmc: PMC7770833
doi:

Substances chimiques

Enzyme Inhibitors 0
Oxazolone 15646-46-5
Acid Ceramidase EC 3.5.1.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15821-15851

Références

J Cell Biol. 1991 Jul;114(1):155-67
pubmed: 2050740
J Biol Chem. 1996 May 24;271(21):12646-54
pubmed: 8647877
J Biol Chem. 2001 Sep 21;276(38):35352-60
pubmed: 11451951
Exp Cell Res. 2015 May 1;333(2):195-200
pubmed: 25770011
J Biol Chem. 2016 Jan 29;291(5):2422-34
pubmed: 26553872
Nat Commun. 2018 Apr 24;9(1):1621
pubmed: 29692406
Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191
pubmed: 29165427
Prog Lipid Res. 2016 Jan;61:51-62
pubmed: 26703189
Cytotechnology. 2018 Feb;70(1):387-396
pubmed: 29230631
PLoS Genet. 2015 Oct 16;11(10):e1005591
pubmed: 26474409
Oncotarget. 2017 Nov 7;8(68):112662-112674
pubmed: 29348854
Essays Biochem. 2020 Sep 23;64(3):565-578
pubmed: 32808655
Mol Neurodegener. 2017 Jan 24;12(1):10
pubmed: 28118852
Biochim Biophys Acta. 2016 Sep;1862(9):1459-71
pubmed: 27155573
J Med Chem. 2020 Apr 9;63(7):3634-3664
pubmed: 32176488
Methods Mol Biol. 2013;1078:9-21
pubmed: 23975817
J Med Chem. 2019 Jan 24;62(2):987-992
pubmed: 30525581
J Pathol. 2016 Jul;239(3):374-83
pubmed: 27126290
Biochem Biophys Res Commun. 2018 Sep 5;503(2):843-848
pubmed: 29920241
Biochim Biophys Acta. 2014 May;1841(5):657-64
pubmed: 23954556
Angew Chem Int Ed Engl. 2015 Jan 7;54(2):485-9
pubmed: 25395373
Cells. 2019 Dec 04;8(12):
pubmed: 31817238
FEBS Lett. 2002 Oct 30;531(1):54-7
pubmed: 12401202
Adv Biol Regul. 2017 Jan;63:122-131
pubmed: 27771292
Eur J Neurosci. 2004 Dec;20(12):3489-97
pubmed: 15610181
Biochimie. 2019 Mar;158:257-264
pubmed: 30703477
Cancer Biol Ther. 2007 Sep;6(9):1455-60
pubmed: 17881906
FASEB J. 2016 Dec;30(12):4159-4171
pubmed: 27609772
J Neurosci Res. 2016 Nov;94(11):990-1006
pubmed: 27638584
Int J Mol Sci. 2017 Feb 17;18(2):
pubmed: 28218669
J Biol Chem. 2010 Mar 12;285(11):7964-76
pubmed: 20068046
Nat Rev Mol Cell Biol. 2003 May;4(5):397-407
pubmed: 12728273
J Lipids. 2011;2011:971618
pubmed: 21490813
Biochim Biophys Acta. 1975 Jul 22;398(1):125-31
pubmed: 238641
Int J Mol Sci. 2020 Feb 26;21(5):
pubmed: 32111095
J Biol Chem. 2011 Aug 12;286(32):27855-62
pubmed: 21693702
J Invest Dermatol. 2008 Feb;128(2):389-97
pubmed: 17713573
Biochim Biophys Acta. 2002 Dec 30;1585(2-3):114-25
pubmed: 12531544
Eur J Cancer. 2016 Jan;52:163-72
pubmed: 26687835
J Med Chem. 2015 Dec 10;58(23):9258-72
pubmed: 26560855
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10032-E10040
pubmed: 30301806
J Am Chem Soc. 2015 Jan 28;137(3):1048-51
pubmed: 25581575
FEBS Lett. 2002 Apr 10;516(1-3):47-52
pubmed: 11959101
J Lipid Res. 2013 May;54(5):1207-20
pubmed: 23423838
Mol Ther. 2009 Mar;17(3):430-8
pubmed: 19107118
Biochim Biophys Acta. 1995 Apr 24;1270(2-3):103-36
pubmed: 7727535
Mol Cancer Ther. 2011 Nov;10(11):2052-61
pubmed: 21885864
Oncotarget. 2016 Apr 5;7(14):18440-57
pubmed: 26943039
Orphanet J Rare Dis. 2018 Jul 20;13(1):121
pubmed: 30029679
J Pathol. 2012 Jan;226(2):241-54
pubmed: 21990005
Apoptosis. 2007 May;12(5):923-39
pubmed: 17294080
Trends Mol Med. 2019 Jan;25(1):20-32
pubmed: 30477968
Adv Biol Regul. 2019 Jan;71:141-146
pubmed: 30389354
ACS Chem Biol. 2019 Jan 18;14(1):11-19
pubmed: 30507149
J Med Genet. 2016 Jun;53(6):389-96
pubmed: 26792856
J Lipid Res. 2014 Sep;55(9):1839-46
pubmed: 24474820
Anal Bioanal Chem. 2015 Jul;407(17):5189-98
pubmed: 25749796
J Med Chem. 2013 May 9;56(9):3518-30
pubmed: 23614460
J Am Chem Soc. 2019 May 15;141(19):7736-7742
pubmed: 31030513
Org Lett. 2004 Aug 19;6(17):2885-8
pubmed: 15330639
J Biol Chem. 1995 May 12;270(19):11098-102
pubmed: 7744740
J Med Chem. 2011 Mar 24;54(6):1539-54
pubmed: 21344906
Chem Phys Lipids. 2006 Oct;144(1):69-84
pubmed: 16942762
Biochim Biophys Acta. 2009 Apr;1793(4):684-96
pubmed: 19111581
Genes Chromosomes Cancer. 2000 Oct;29(2):137-46
pubmed: 10959093
Sci Rep. 2013;3:1035
pubmed: 23301156
J Med Chem. 2017 Jul 13;60(13):5800-5815
pubmed: 28603987
Proc Natl Acad Sci U S A. 2019 Oct 1;116(40):20097-20103
pubmed: 31527255
FEBS Lett. 2016 Mar;590(6):716-25
pubmed: 26898341

Auteurs

Samantha Caputo (S)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy.

Simona Di Martino (S)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy.

Vincenzo Cilibrasi (V)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy.

Piero Tardia (P)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy.

Marco Mazzonna (M)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy.

Debora Russo (D)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
D3-Pharma Chemistry, Via Morego 30, I-16163 Genova, Italy.

Ilaria Penna (I)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
D3-Pharma Chemistry, Via Morego 30, I-16163 Genova, Italy.

Maria Summa (M)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy.

Sine Mandrup Bertozzi (SM)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy.

Natalia Realini (N)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy.

Natasha Margaroli (N)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy.

Marco Migliore (M)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy.

Giuliana Ottonello (G)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy.

Min Liu (M)

Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States.

Peter Lansbury (P)

Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States.

Andrea Armirotti (A)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy.

Rosalia Bertorelli (R)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Analytical Chemistry and Translational Pharmacology, Via Morego 30, I-16163 Genova, Italy.

Soumya S Ray (SS)

Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States.

Renato Skerlj (R)

Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States.

Rita Scarpelli (R)

Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy.
Drug Discovery and Development (D3)-Validation, Via Morego 30, I-16163 Genova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH